Castration-Resistant Prostate Cancer (CRPC) Treatment Market size to grow by USD 5.98 billion from 2023 to 2028, North America to account for 47% of market growth- Technavio : vimarsana.com

Castration-Resistant Prostate Cancer (CRPC) Treatment Market size to grow by USD 5.98 billion from 2023 to 2028, North America to account for 47% of market growth- Technavio

/PRNewswire/ -- The castration-resistant prostate cancer (CRPC) treatment market is expected to grow by USD 5.98 billion from 2023 to 2028. In addition, the...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , America , Klinikum Gmb , Jesse Maida , Daiichi Sankyo Co , Technavio Research , Company Profile , Oncology Research , F Hoffmann La Roche Ltd , Everest Pharmaceuticals Ltd , Amgen Inc , Company Analysis , Allarity Therapeutics Inc , Health Economics , Company Landscape , Beigene Ltd , Amneal Pharmaceuticals Inc , Pfizer Inc , Ono Pharmaceutical Co , Merck Kga , Merck Kgaa , Dr Reddys Laboratories Ltd , Robotic Prostate Centre Cambridge , Bayer Ag , Astellas Pharma Inc , Drug Development Pipeline , Biopharmaceutical Companies , North America , North Americais , Daiichi Sankyo , Medias Klinikum Gmbh , Focal Therapy Clinic , Ono Pharmaceutical , Castration Resistant Prostate Cancer , Resistant Prostate Cancer , Treatment Market , Androgen Deprivation Therapy , Abiraterone Acetate , Prostate Specific Membrane Antigen , Clinical Trials , Hormone Refractory Prostate Cancer , Novel Therapeutics , Personalized Medicine , Treatment Resistance Mechanisms , Genetic Testing , Market Trends , Healthcare Policies , Global Market Analysis , Technavio ,